IN THE SPOTLIGHT

肺癌之声丨关印教授:当 HER2 突变 NSCLC 治疗迈入深水区,如何构建个体化诊疗「三维地图」_腾讯新闻

肺癌之声丨关印教授:当 HER2 突变 NSCLC 治疗迈入深水区,如何构建个体化诊疗「三维地图」_腾讯新闻

Unravelling the molecular genetics and epigenetic regulation of lung cancer vis a vis non-small cell lung cancer (NSCLC) for a targeted approach towards novel therapeutic strategies: a review

Unravelling the molecular genetics and epigenetic regulation of lung cancer vis a vis non-small cell lung cancer (NSCLC) for a targeted approach towards novel therapeutic strategies: a review

Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS

Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS

Precision Oncology in HER2-Mutated NSCLC: Strategies for Today and Tomorrow

Precision Oncology in HER2-Mutated NSCLC: Strategies for Today and Tomorrow

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial

Commentary on early survival gains from adding radiotherapy to ımmunotherapy in bone-metastatic NSCLC

Commentary on early survival gains from adding radiotherapy to ımmunotherapy in bone-metastatic NSCLC